Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:abacavir
gptkb:lamivudine |
| gptkbp:approvedBy |
gptkb:EMA
gptkb:MHRA gptkb:TGA |
| gptkbp:ATCCode |
gptkb:J05AR02
|
| gptkbp:contraindication |
severe liver impairment
HLA-B*5701 positive |
| gptkbp:drugClass |
antiretroviral therapy
nucleoside reverse transcriptase inhibitor combination |
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kivexa
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:ViiV_Healthcare
|
| gptkbp:marketedIn |
gptkb:Australia
gptkb:European_Union gptkb:United_Kingdom |
| gptkbp:pregnancyCategory |
C (US)
B3 (Australia) |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache hypersensitivity reaction |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:abacavir
gptkb:lamivudine |
| gptkbp:bfsLayer |
6
|